Skip to content
Open access

Preliminary study of individualized therapy for ventricular septal defect with severe pulmonary arterial hypertension.

Sep 2026 · Clinical and experimental hypertension · Vol 48 1, pp. 2734004 · 0 citations · 18 references
Medicine

TL;DR

Combining SaO2 with RHC-derived parameters provides a more comprehensive and individualized assessment of disease severity in VSD-PAH than hemodynamics alone and may provide a hypothesis-generating framework for cardiovascular specialists.

Abstract

Background

Pulmonary arterial hypertension (PAH) is a serious complication of congenital heart disease (CHD) with a left-to-right shunt, particularly ventricular septal defect (VSD). In patients presenting with severe PAH, therapeutic decision-making remains challenging because precise and individualized assessment criteria are lacking. In current clinical practice, treatment strategies are often based mainly on isolated hemodynamic parameters obtained by right heart catheterization (RHC), which may not fully reflect disease severity or reversibility.

Objectives

This study aimed to explore an individualized treatment strategy for patients with severe VSD-PAH by analyzing the relationships among peripheral arterial oxygen saturation (SaO2), pulmonary vascular resistance (PVR), pulmonary-to-systemic blood flow ratio (Qp/Qs), and pulmonary-to-systemic pressure ratio (Pp/Pa).

Methods

We retrospectively analyzed 121 patients with isolated VSD and severe PAH admitted to our center between 2010 and 2020. All patients underwent RHC. Correlations between SaO2 and PVR, Qp/Qs, and Pp/Pa were assessed using Spearman correlation analysis. Patients were stratified according to SaO2 levels, and treatment strategies were compared across different hemodynamic profiles using Fisher's exact test. Based on these findings, we established a scoring system integrating SaO2, PVR, Qp/Qs, and Pp/Pa, and categorized total scores to examine their association with actual treatment strategies.

Results

The distribution of treatment strategies differed significantly across combinations of SaO2 and PVR, whereas Qp/Qs and Pp/Pa provided limited additional discrimination when SaO2 exceeded 93%. The proposed scoring system was associated with observed treatment patterns: patients with total scores ≥ 60 were predominantly managed surgically (with or without preoperative medical therapy), whereas those with scores <40 were mainly treated with medical therapy alone (93.7%). Intermediate score ranges were associated with mixed treatment patterns.

Conclusions

Combining SaO2 with RHC-derived parameters provides a more comprehensive and individualized assessment of disease severity in VSD-PAH than hemodynamics alone. The proposed multidimensional scoring system may provide a hypothesis-generating framework for cardiovascular specialists.

Read PDF

Similar papers

Open access Oct 2026

Right heart dimensions and pulmonary arterial wedge pressure in pulmonary arterial hypertension: exploring a controversial relationship

Investigating the relationship between right and left ventricular dimensions, and their association with LVEDP, estimated via pulmonary capillary wedge pressure (PCWP), in a large, multicenter cohort of patients with pulmonary arterial hypertension (PAH) revealed a relatively balanced distribution across low, intermedi...

S. Papa, R. Badagliacca, F. Lo Giudice et al. · 0 citations
Open access Sep 2026

Flow versus resistance: hemodynamic phenotyping of pulmonary hypertension in infants with shunts and concurrent lung disease

Neonatal pulmonary hypertension (PH) can be categorized into three distinct physiologies: resistance-driven precapillary pulmonary arterial hypertension (PAH), flow-driven precapillary PH, and postcapillary PH. We present eight patients, divided into three groups: premature infants with BPD, infants with chronic respir...

T. Gonzalez, C. Simpkin, Paula Dias Maia et al. · 0 citations
Nov 2026

Abstract 15107: Clinical Features, Hemodynamics and Outcomes of Pulmonary Hypertension in Adults with Congenital Heart Disease and Heart Failure with Reduced Ejection Fraction

Background: Although pulmonary hypertension (PH) and heart failure (HF) with reduced ejection fraction (HFrEF) occur in adults with congenital heart disease (CHD), the relationship between PH and HFrEF has not been systematically studied in this population. We sought to define the clinical characteristics, hemodynam...

Amr Moustafa, Ahmed T. Abdelhalim, Z. Kholeif et al. · 0 citations
Open access Nov 2026

Obstructive Ventilatory Defects in Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension.

Background/Objectives: Patients with pulmonary arterial hypertension (PAH) may display obstructive ventilatory defects outside of defined obstructive lung disease. However, its pathogenesis and prognostic relevance remain unknown. Similar data have emerged for patients with chronic thromboembolic pulmonary hypertension...

T. Sonneck, M. Barnikel, P. Arnold et al. · 0 citations
Open access Oct 2026

Right ventricular remodelling in pulmonary arterial hypertension after sotatercept therapy

The expanding therapeutic armamentarium for pulmonary arterial hypertension (PAH), including the recent approval of sotatercept, is shifting treatment goals beyond achieving low-risk status towards haemodynamic improvement and right ventricular (RV) recovery. In this context, there is growing interest in echocard...

E. G. Ortiz, I. M. de Miguel, A. Cruz-Utrilla et al. · 0 citations
Open access Oct 2026

Right ventricular myocardial performance score predicts 1 year mortality in pulmonary arterial hypertension

Multiparametric risk stratification is essential to determine prognosis and treatment in pulmonary arterial hypertension (PAH). Aside from right atrial pressure, traditional hemodynamic variables at diagnosis have an inconsistent association with prognosis in contemporary PAH cohorts. Hemodynamic indices of right...

L. Gozdecki, M. Patel, J. Han et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.